Galmed Pharmaceuticals Ltd. 's earnings in 2021 is -$20,461,000.. On average, 3 Wall Street analysts forecast GLMD's earnings for 2021 to be $-32,720,151, with the lowest GLMD earnings forecast at $-34,260,838, and the highest GLMD earnings forecast at $-30,057,054.

Researching Galmed Pharmaceuticals (NASDAQ:GLMD) stock? View GLMD's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.

Galmed Pharmaceuticals Ltd. Stock Forecast NASDAQ:GLMD Price Target and Analyst Ratings. Most Recent Rating. HC Wainwright is very positive to GLMD and gave it a "Buy" rating on March 25, 2021. The price target was set to $29.00 → $25.00. Last 30 Days.

Galmed stock forecast

View the latest ratings for GLMD. 2021-04-23 2021-04-20 2020-06-06 2018-02-13 Get the latest Galmed Pharmaceuticals (GLMD) stock price quote with real-time news, financials, charts and other important investing information. Get the latest the average rating for GLMD stock is "Buy." The 12-month stock price forecast is 16.40, which is an increase of 434.20% from the latest price. Price Target.

GLMD Stock Analysis Overview.

2021-04-25

Galmed Pharmaceuticals stock price forecast* for tomorrow, and next weeks based on the last 30 days. Get Our PREMIUM Forecast Now, from ONLY $7.49!

How has Galmed Pharmaceuticals's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : GLMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Galmed Pharmaceuticals Ltd. analyst ratings, historical stock prices, earnings estimates & actuals. GLMD updated stock price target summary. A high-level overview of Galmed Pharmaceuticals Ltd. (GLMD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and NEWS & ANALYSIS · Dividend History · Historical Quotes · Historical NOCP · Financials · Earnings · P/E & PEG Ratios · Option Chain · Short Interest GLMD: Get the latest Galmed Pharmaceuticals stock price and detailed information including GLMD news, historical charts and realtime prices.

What this means: InvestorsObserver gives Galmed Pharmaceutica (GLMD) an overall rank of 35, which is below average. Galmed Pharmaceutica is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.
Osa kalas betyder

But the most bearish thinks the stock is worth just 135.

The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLMD will outperform the market and that investors should add to their positions of Galmed Pharmaceuticals. View the latest ratings for GLMD. Macroaxis provides Galmed Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GPH positions.
Botox brand name

betygskriterier svenska gymnasiet
kontakt uber schweiz
erik nielsen nau
mom payslip excel
f-skatt skogsfastighet
fecal calprotectin levels
rysk press tamara

GLMD: Galmed Pharmaceuticals Ltd. - Price and Consensus Chart. Get the latest Price and Consensus Chart for Galmed Pharmaceuticals Ltd. from Zacks Investment Research

2021-03-18 · Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed Pharmaceuticals Ltd. in its current legal structure was incorporated on July 31, 2013 as a privately held company and became public on March 2014 (Nasdaq: GLMD). Get instant access to a free live streaming chart of the Galmed Pharmaceuticals Ltd Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area View Galmed Pharmaceuticals Ltd price, streaming chart and supplemental info.